MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing

Related Keywords

Karim Dabbagh ,Jean Marie Lefebvre ,Jean Volatier ,Bpifrance Investissement ,Nadia Kamal ,Kepler Cheuvreux ,Claude Bertrand ,Senior Pr Corporate Communications ,Company Universal Registration Document ,Trophic Communications ,Regulatory News ,Microbiome Ecosystem ,Extraordinary General Meeting ,Seventure Partners ,Chief Executive Officer ,Annual General Meeting ,Universal Registration ,General Meeting ,Maat Pharma ,Microbiome Ecosystem Therapies ,Euronext Paris ,Investor Relations ,Communications Manager ,Ihr Portfolio ,